Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesenchymal stem cell therapy (HepaStem) - Cellaion

Drug Profile

Mesenchymal stem cell therapy (HepaStem) - Cellaion

Alternative Names: hALDMSC - Cellaion; HepaStem; Heterologous Human Adult Liver derived Progenitor Cells; HHALPC; human Adult Liver-Derived Mesenchymal Progenitor/Stem Cells - Cellaion

Latest Information Update: 17 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catholic University of Louvain
  • Developer Cellaion; LifeLiver; Promethera Biosciences
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cartilage replacements; Cell replacements; Osteogenesis stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crigler-Najjar syndrome; Inborn urea cycle disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Inborn urea cycle disorders
  • Phase II Crigler-Najjar syndrome; Liver failure
  • Phase I/II Non-alcoholic steatohepatitis
  • No development reported Haemophilia; Hepatic fibrosis
  • Discontinued Glycogen storage disease type I; Phenylketonuria

Most Recent Events

  • 21 Jun 2023 Efficacy and pharmacodynamics data from phase I/II PANASH trial were presented at the European Association for the Study of the Liver Congress (EASL-2023)
  • 28 Dec 2020 No recent reports of development identified for research development in Haemophilia in Belgium (Parenteral)
  • 31 Aug 2020 Promethera Biosciences completes phase I/II clinical trials in Non-alcoholic steatohepatitis (In the elderly, In adults) in Spain, Poland, France, Bulgaria, Belgium and Romania (IV, Infusion) (NCT03963921)(EudraCT2018-004449-18)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top